|Bid||105.71 x 300|
|Ask||105.73 x 100|
|Day's Range||103.00 - 105.86|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||24.78|
|Earnings Date||Jan 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||123.91|
Buyouts are the order of the day in the biotechnology sector this week, with a couple of big-name acquisitions dominating market sentiment heading into the US open on Tuesday. Celgene Corporation (NASDAQ:CELG) leads the pack with its just reported acquisition of Juno Therapeutics Inc (NASDAQ:JUNO), while Novartis AG (NYSE:NVS) announced the successful completion of a […] The post Celgene, Novartis Both Report Billion Dollar Buyouts appeared first on Market Exclusive.
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.
Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. Learn why this deal is important to the biotech sector.
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Celgene is acquiring Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. The author analyzes the price per share and returns over each of the biotech's funding rounds.
- ORGS is an Overlooked Cell Therapy Manufacturer and Developer Working with Major Biotech Companies like Servier, CRISPR (CRSP), and Adaptimmune (ADAP), Among Others - Celgene-Juno and Gilead-Kite Deals ...
Celgene and Sanofi are the latest big drugmakers willing to pay hefty premiums for acquisitions amid an increasingly scarce roster of companies with promising products.
Juno Therapeutics Inc. and CEO Hans Bishop emailed employees, founders and vendors Monday morning to let them know of the company's $9 billion deal to sell to Celgene Corp. "For many of us this is a surprising development, and I am sure comes with some mixed emotions," he told employees. Celgene i ncreased its investment in Seattle-based Juno last year after the failure of its flagship drug trail .
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
Celgene will buy Juno Therapeutics for $9 billion and French pharma Sanofi will pay $11.6 billion for Bioverativ.
Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream.
U.S. stocks advanced on Monday as each of Wall Street's main scored records in the wake of a deal by U.S. senators to end the federal government shutdown. Legislation to renew federal funding to the government cleared a procedural hurdle in the Senate and was expected soon to pass votes in the Senate and House of Representatives, allowing government to re-open through Feb 8.
Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.
Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.